Earlier this week, FOX Business ran a segment about the biopharmaceutical marketplace.
For biopharmaceutical companies that rely upon volunteers to participate in clinical research on potential new medicines, protecting privacy has always been a priority.
I've lost count of the number of times I've heard the same refrain about the need for more patients to participate in clinical trials of new medicines.
I've been hearing that over and over like a broken record for almost 1.5 years since we started rolling out "Research in Your Backyard" reports about trials conducted in the states by our biopharmaceutical companies in collaboration with local research institutions.
01.28.13 | By Karl Uhlendorf
Many of The Catalyst posts this month have discussed different aspects of innovation, and this week, we focused on one of the most important elements: research and development.
While the "Innovations and Inaugurations" series came to an end last week, we remain focused on the importance of collaboration between public and private partners to help advance innovation and the critical role that biopharmaceutical research companies play in improving health care for patients battling disease.
Last week we released a new report by Analysis Group examining innovation in the biopharmaceutical pipeline.
Last week, the National Institutes of Health announced its support of four new studies aimed at finding new treatments for Alzheimer's disease.
As my predecessor noted, PDUFA is indeed a weird word worth knowing.
Last week, PhRMA released a new report highlighting the fact that there are more than 5,000 medicines in development, 70 percent of which are potential first-in-class medicines that can help patients with serious unmet medical needs. The authors of the report found that a sizable percentage of the potential first-in-class medicines focus on diabetes.
01.18.13 | By Kaelan Hollon
Hope is more than just a presidential theme; it is what inspires us all to do more for those who have less, it represents the promise of a better tomorrow and for millions of patients living with disease, it is what gives them the strength to hold on a little longer for a new treatment that can help